Charles River Laboratories International (CRL) Income from Discontinued Operations (2009 - 2018)
Charles River Laboratories International (CRL) posted Income from Discontinued Operations of $1.5 million for Q2 2018, up 6747.83% on a QoQ basis from -$23000.0 in Q1 2018, and up 2253.52% year-over-year from $64966.5 in Q2 2017.
Analysis
Charles River Laboratories International (CRL) Income from Discontinued Operations (2009 - 2018) Analysis & Trends
Charles River Laboratories International has reported Income from Discontinued Operations for 10 years, with the latest figure at $1.5 million in Q2 2018.
- On a quarterly basis, Income from Discontinued Operations rose 2253.52% year-over-year to $1.5 million in Q2 2018; TTM through Mar 2019 was $1.5 million, a 1080.13% increase from a year earlier, with the FY2018 full-year figure at $1.5 million, up 1199.27% from the prior year.
- Income from Discontinued Operations was $1.5 million for Q2 2018 at Charles River Laboratories International, up from -$23000.0 in the prior quarter.
- The five-year high for Income from Discontinued Operations was $1.5 million in Q2 2018, with the low at -$902000.0 in Q4 2015.
- Average Income from Discontinued Operations over 5 years is -$57055.6, with a median of -$24500.0 recorded in 2016.
- The sharpest annual moves came in 2014 and 2018: Income from Discontinued Operations slumped 953.66% in 2014, then soared 2253.52% in 2018.
- Over 5 years, Income from Discontinued Operations stood at -$864000.0 in 2014, then slipped by 4.4% to -$902000.0 in 2015, then soared by 94.68% to -$48000.0 in 2016, then soared by 52.08% to -$23000.0 in 2017, then soared by 6747.83% to $1.5 million in 2018.
- The last three Income from Discontinued Operations figures came in at $1.5 million (Q2 2018), -$23000.0 (Q1 2018), and -$23000.0 (Q4 2017), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.72 Bn | 42.64 Bn | 1.44 Bn | - |
| 2 | Medpace Holdings | 17.37 Bn | 16.87 Bn | 201.64 Mn | - |
| 3 | Icon | 13.65 Bn | 12.72 Bn | 479.29 Mn | - |
| 4 | Charles River Laboratories International | 13.13 Bn | 12.94 Bn | 452.07 Mn | - |
| 5 | Fortrea Holdings | 1.89 Bn | 1.72 Bn | 139.20 Mn | - |
| 6 | Evotec SE | 574.75 Mn | 148.87 Mn | - | - |
| 7 | Ginkgo Bioworks Holdings | 439.63 Mn | 355.09 Mn | 18.44 Mn | 10.61 Mn |
| 8 | Champions Oncology | 69.43 Mn | 65.03 Mn | 7.70 Mn | - |
| 9 | MindWalk Holdings | 51.76 Mn | 46.29 Mn | 1.61 Mn | - |
| 10 | VivoSim Labs | 1.37 Mn | 1.37 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2018 | 1.53 Mn |
| Mar 31, 2018 | -23,000.00 |
| Dec 30, 2017 | -23,000.00 |
| Sep 30, 2017 | -39,000.00 |
| Jul 1, 2017 | -71,000.00 |
| Apr 1, 2017 | -4,000.00 |
| Dec 31, 2016 | -48,000.00 |
| Sep 24, 2016 | 342,000.00 |
| Jun 25, 2016 | 12,000.00 |
| Mar 26, 2016 | -26,000.00 |
| Dec 26, 2015 | -902,000.00 |
| Sep 26, 2015 | -34,000.00 |
| Jun 27, 2015 | -7,000.00 |
| Mar 28, 2015 | -7,000.00 |
| Dec 27, 2014 | -864,000.00 |
| Sep 27, 2014 | 52,000.00 |
| Jun 28, 2014 | -644,000.00 |
| Mar 29, 2014 | -270,000.00 |
| Dec 28, 2013 | -82,000.00 |
| Sep 28, 2013 | -113,000.00 |